News
🇺🇸 AmericasLatest pharmaceutical news, drug approvals, and FDA regulatory updates
Latest News
FDA Approves VitaCorp Antibiotic: Breakthrough for Multi-Drug Resistant Infections
The FDA has approved VitaCorp antibiotic, marking a significant advancement in the fight against multi-drug resistant infections and improving patient outcomes.
FDA Approves NeuroVance XR: New Pediatric ADHD Extended-Release Option
The FDA has approved NeuroVance XR, a groundbreaking extended-release medication for pediatric ADHD, offering a new solution for effective symptom management.
FDA Approves LumaGen Gene Therapy for Inherited Retinal Disease
The FDA has granted approval for LumaGen, a groundbreaking gene therapy designed to treat inherited retinal disease, potentially restoring vision for many patients.
FDA Approves Biosimilar Insulin Lispro: What You Need to Know
The FDA has approved a biosimilar version of insulin lispro, offering a new option for diabetes management and potentially lowering treatment costs.
FDA Approval TRK Inhibitor: OncoCure's Breakthrough for NTRK Tumors
OncoCure has achieved FDA approval for its innovative TRK inhibitor, offering new hope for patients with NTRK tumors and advancing targeted cancer treatment.
FDA Approves CART-T20: Novel CAR-T Therapy for Mantle Cell Lymphoma
The FDA has approved CART-T20, a novel CAR-T therapy designed to treat mantle cell lymphoma, marking a significant advancement in cancer treatment options.
FDA Blockchain Pilot Program: Enhancing Pharmaceutical Supply Chain Security
The FDA Blockchain Pilot Program is set to revolutionize the pharmaceutical supply chain, ensuring enhanced security and traceability for critical drugs.
FDA to Launch AI-Powered Drug Review System by 2027
The FDA plans to implement an AI-powered drug review system by 2027, aiming to enhance the efficiency and accuracy of drug approvals for various indications.
FDA Approves RenoProtect: New Therapy to Slow Diabetic Kidney Disease
The FDA has approved RenoProtect, a novel therapy designed to slow the progression of diabetic kidney disease, marking a significant advancement in patient care.
FDA Approves AirFlow: New Inhalable Treatment for Severe Asthma
The FDA has approved AirFlow, a novel inhalable treatment for severe asthma, promising improved management and quality of life for patients.
FDA Approves OsteoBuild: New Bone-Building Agent for Severe Osteoporosis
The FDA has approved OsteoBuild, a revolutionary bone-building agent designed to treat severe osteoporosis, offering new hope for patients at risk of fractures.
FDA Approves ArterioFlow: Minimally Invasive PAD Treatment by CardioMed
CardioMed's ArterioFlow receives FDA approval as a groundbreaking minimally invasive treatment for Peripheral Artery Disease (PAD), promising improved outcomes.
FDA Priority Review Granted to PharmaGiant's CholesterolRx for High Cholesterol
PharmaGiant's CholesterolRx has received FDA Priority Review for high cholesterol, potentially revolutionizing treatment options for millions of patients.
FDA Approves OptiSight: New VisionCare Glaucoma Treatment
The FDA has officially approved OptiSight, a novel treatment for glaucoma, promising enhanced vision care and improved outcomes for patients.
FDA Approves MicroBalance: New Microbiome Therapy for Crohn's Disease
The FDA has approved MicroBalance, a novel microbiome therapy designed to treat Crohn's Disease, marking a significant advancement in patient care.
FDA Approves SomniRestore: New Chronic Insomnia Treatment
The FDA has officially approved SomniRestore, a new treatment for chronic insomnia, promising to help millions achieve restful sleep and enhance their overall well-being.
FDA Approves NeuroBloc: Non-Opioid Relief for Chronic Neuropathic Pain
NeuroBloc has received FDA approval as a non-opioid treatment for chronic neuropathic pain, providing an innovative alternative for pain relief.
FDA Approves LysoClear: New Treatment for Lysosomal Storage Disorders
The FDA has officially approved LysoClear, a novel therapy designed to treat lysosomal storage disorders, marking a significant advancement in patient care.
FDA Breakthrough Therapy TargTex TX202: What You Need to Know
TargTex TX202 is an FDA breakthrough therapy designed to treat advanced melanoma, offering new hope and innovative treatment options for patients.
FDA Approves BriaCell's Bria-IMT: Novel CAR-T Therapy for Advanced Breast Cancer
BriaCell's Bria-IMT has received FDA approval as a novel CAR-T therapy, providing a promising treatment option for patients with advanced breast cancer.